反常性痤疮/化脓性汗腺炎病情评价标准研究进展

doi:10.35541/cjd.20210236

Abstract

Abstract: 【Abstract】 The degree of severity varies greatly among different patients with acne inversa（AI）/hidradenitis suppurativa（HS）, and disease severity usually determines treatment strategies. There have been a number of severity assessment criteria for AI/HS, such as the Hurley grading system, Sartorius score, HS severity index, etc., which have been widely used in clinical classification and research and have shown clinical guiding significance. However, limitations still exist in some criteria, such as low sensitivity for efficacy evaluation, limited application range, etc. This review introduces several severity assessment criteria for AI/HS that have been proposed in recent years, aiming to better evaluate the disease and carry out graded treatment.

Key words: Hidradenitis suppurativa, Severity of illness index, Severity assessment criteria

Ma Xiao, Li Chengrang, Wang Baoxi, He Yanyan, Xu Haoxiang. Severity assessment criteria for acne inversa/hidradenitis suppurativa[J]. Chinese Journal of Dermatology, 2024, 57(3): 283-286.doi:10.35541/cjd.20210236

References ［30］

［1］	中国反常性痤疮/化脓性汗腺炎诊疗专家共识制订小组. 中国反常性痤疮/化脓性汗腺炎诊疗专家共识（2021版）［J］. 中华皮肤科杂志, 2021,54（2）:97⁃104. doi: 10.35541/cjd.20200802.
［2］	Kokolakis G, Wolk K, Schneider⁃Burrus S, et al. Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system［J］. Dermatology, 2020,236（5）:421⁃430. doi: 10.1159/000508787.
［3］	Thorlacius L, Cohen AD, Gislason GH, et al. Increased suicide risk in patients with hidradenitis suppurativa［J］. J Invest Dermatol, 2018,138（1）:52⁃57. doi: 10.1016/j.jid.2017.09.008.
［4］	Ingram JR. Refining the hidradenitis suppurativa Hurley staging system for mild, moderate and severe disease［J］. Br J Dermatol, 2019,180（5）:991⁃992. doi: 10.1111/bjd.17769.
［5］	Rondags A, van Straalen KR, van Hasselt JR, et al. Correlation of the refined Hurley classification for hidradenitis suppurativa with patient⁃reported quality of life and objective disease severity assessment［J］. Br J Dermatol, 2019,180（5）:1214⁃1220. doi: 10.1111/bjd.17508.
［6］	Horváth B, Janse IC, Blok JL, et al. Hurley staging refined: a proposal by the Dutch Hidradenitis Suppurativa Expert Group［J］. Acta Derm Venereol, 2017,97（3）:412⁃413. doi: 10.2340/00015555⁃2513.
［7］	Rondags A, Volkering RJ, Turcan I, et al. The refined Hurley patient questionnaire: an accurate self⁃assessment instrument for deriving the correct refined Hurley stage in hidradenitis suppurativa［J］. Acta Derm Venereol, 2019,99（7）:703⁃704. doi: 10.2340/00015555⁃3126.
［8］	Zouboulis CC, Tzellos T, Kyrgidis A, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System （IHS4）, a novel dynamic scoring system to assess HS severity［J］. Br J Dermatol, 2017,177（5）:1401⁃1409. doi: 10. 1111/bjd.15748.
［9］	Caposiena Caro RD, Cannizzaro MV, Botti E, et al. Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: Clinical and ultrasound observations［J］. J Am Acad Dermatol, 2019,80（5）:1314⁃1321. doi: 10.1016/j.jaad.2018.11. 035.
［10］	Zouboulis CC, Hansen H, Caposiena Caro RD, et al. Adalimumab dose intensification in recalcitrant hidradenitis suppurativa/acne inversa［J］. Dermatology, 2020,236（1）:25⁃30. doi: 10.1159/000503606.
［11］	Napolitano M, Mastroeni S, Fusari R, et al. The International Hidradenitis Suppurativa Severity Score System （IHS4） is a valuable tool to assess gender⁃associated differences［J］. Eur J Dermatol, 2020,30（2）:201⁃203. doi: 10.1684/ejd.2020.3743.
［12］	Hessam S, Scholl L, Sand M, et al. A novel severity assessment scoring system for hidradenitis suppurativa［J］. JAMA Dermatol, 2018,154（3）:330⁃335. doi: 10.1001/jamadermatol.2017.5890.
［13］	Nielsen RM, Lindsø Andersen P, Sigsgaard V, et al. Pain perception in patients with hidradenitis suppurativa［J］. Br J Dermatol, 2020,182（1）:166⁃174. doi: 10.1111/bjd.17935.
［14］	Goldfarb N, Ingram JR, Jemec G, et al. Hidradenitis Suppurativa Area and Severity Index （HASI）: a pilot study to develop a novel instrument to measure the physical signs of hidradenitis suppurativa［J］. Br J Dermatol, 2020,182（1）:240⁃242. doi: 10. 1111/bjd.18335.
［15］	Chiricozzi A, Bettoli V, De Pità O, et al. HIDRAdisk: an innovative visual tool to assess the burden of hidradenitis suppurativa［J］. J Eur Acad Dermatol Venereol, 2019,33（1）:e24⁃e26. doi: 10.1111/jdv.15122.
［16］	Peris K, Lo Schiavo A, Fabbrocini G, et al. HIDRAdisk: validation of an innovative visual tool to assess the burden of hidradenitis suppurativa［J］. J Eur Acad Dermatol Venereol, 2019,33（4）:766⁃773. doi: 10.1111/jdv.15425.
［17］	Marzano AV, Chiricozzi A, Giovanardi G, et al. Creation of a severity index for hidradenitis suppurativa that includes a validated quality⁃of⁃life measure: the HIDRAscore［J］. J Eur Acad Dermatol Venereol, 2020,34（8）:1815⁃1821. doi: 10.1111/jdv.16328.
［18］	Kirby JS, Butt M, King T. Severity and Area Score for Hidradenitis （SASH）: a novel outcome measurement for hidradenitis suppurativa［J］. Br J Dermatol, 2020,182（4）:940⁃948. doi: 10.1111/bjd.18244.
［19］	Goldfarb N, Lowes MA, Butt M, et al. Hidradenitis Suppurativa Area and Severity Index Revised （HASI⁃R）: psychometric property assessment［J］. Br J Dermatol, 2021,184（5）:905⁃912. doi: 10.1111/bjd.19565.
［20］	Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician′s Global Assessment［J］. J Am Acad Dermatol, 2004,51（4）:563⁃569. doi: 10.1016/j.jaad.2004.04.012.
［21］	Kimball AB, Jemec GB, Yang M, et al. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response （HiSCR） as the clinical endpoint for hidradenitis suppurativa treatment［J］. Br J Dermatol, 2014,171（6）:1434⁃1442. doi: 10.1111/bjd.13270.
［22］	Frew JW, Jiang CS, Singh N, et al. Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: a post hoc analysis of PIONEER 1 and 2 individual patient data［J］. J Am Acad Dermatol, 2020,82（5）:1150⁃1157. doi: 10.1016/j.jaad.2019.12.044.
［23］	Kimball AB, Sobell JM, Zouboulis CC, et al. HiSCR （Hidradenitis Suppurativa Clinical Response）: a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo⁃controlled portion of a phase 2 adalimumab study［J］. J Eur Acad Dermatol Venereol, 2016,30（6）:989⁃994. doi: 10.1111/jdv.13216.
［24］	Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial［J］. Ann Intern Med, 2012,157（12）:846⁃855. doi: 10.7326/0003⁃4819⁃157⁃12⁃201212180⁃00004.
［25］	Sartorius K, Emtestam L, Jemec GB, et al. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity［J］. Br J Dermatol, 2009,161（4）:831⁃839. doi: 10. 1111/j.1365⁃2133.2009.09198.x.
［26］	Amano M, Grant A, Kerdel FA. A prospective open⁃label clinical trial of adalimumab for the treatment of hidradenitis suppurativa［J］. Int J Dermatol, 2010,49（8）:950⁃955. doi: 10.1111/j.1365⁃4632.2010.04545.x.
［27］	Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double⁃blind, placebo⁃controlled crossover trial［J］. J Am Acad Dermatol, 2010,62（2）:205⁃217. doi: 10.1016/j.jaad. 2009.06.050.
［28］	Akdogan N, Dogan S, Incel⁃Uysal P, et al. Serum amyloid A and C⁃reactive protein levels and erythrocyte sedimentation rate are important indicators in hidradenitis suppurativa［J］. Arch Dermatol Res, 2020,312（4）:255⁃262. doi: 10.1007/s00403⁃019⁃02014⁃8.
［29］	Hessam S, Sand M, Gambichler T, et al. Correlation of inflammatory serum markers with disease severity in patients with hidradenitis suppurativa （HS）［J］. J Am Acad Dermatol, 2015,73（6）:998⁃1005. doi: 10.1016/j.jaad.2015.08.052.
［30］	Wortsman X, Moreno C, Soto R, et al. Ultrasound in⁃depth characterization and staging of hidradenitis suppurativa［J］. Dermatol Surg, 2013,39（12）:1835⁃1842. doi: 10.1111/dsu.12329.

[1]	Zhang Yue, Tao Meng, Li Min, Jiang Peiyu, Liu Yunyi, Liu Yixuan, Pan Ruoxin, Xu Yang. Severity assessment criteria for rosacea [J]. Chinese Journal of Dermatology, 2024, 57(2): 182-185.
[2]	Wang Wenzhu, Wang Baoxi, He Yanyan, Xu Haoxiang. Clinical phenotypes and genotypes of hidradenitis suppurativa/acne inversa [J]. Chinese Journal of Dermatology, 2023, 56(9): 892-895.
[3]	Yuan Chen, Yan Yan, Wang Baoxi . Biotherapy for acne inversa [J]. Chinese Journal of Dermatology, 2023, 56(3): 270-273.
[4]	Zhang Shuai, Shao Yi, Zhang Shoumin, Li Zhenlu, Li Jianguo, Wang Jianbo. Clinical manifestations and genetic variation analysis of one case of tuberous sclerosis complex complicated by acne inversa [J]. Chinese Journal of Dermatology, 2023, 0(3): 20230268-e20230268.
[5]	Wang Qian, Qi Bo, Zhang Lixia, Liu Wei, Lan Yunping. Comparison of the performance of SCORTEN and ABCD-10 in evaluating the prognosis of Stevens-Johnson syndrome/toxic epidermal necrolysis [J]. Chinese Journal of Dermatology, 2022, 55(7): 566-570.
[6]	Huang Yaxin, He Yuanmin, Huang Shuli, Xiong Xia, Deng Yongqiong. An investigation into clinical significance of serum chitinase 3-like protein 1 in pemphigus vulgaris [J]. Chinese Journal of Dermatology, 2022, 55(6): 523-527.
[7]	Shen Chen, Tao Juan. Evolution of assessment of long-term control of and treat-to-target in atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(5): 442-445.
[8]	Fu Chao, Wu Jiaona, Lang Wenchao, Gao Fei, Niu Guiye, Bian Peiwen, Gao Minhong, Si Xiaoqing, Xin Linlin. Role of dermoscopy in assessing vitiligo activity [J]. Chinese Journal of Dermatology, 2022, 55(3): 268-271.
[9]	Li Wenrui, Jia Weixue, Zhang Yunbin, Lin Lin, Li Chengrang. Construction of a nicastrin gene-silenced zebrafish model and a primary study on the mechanism of abnormal pigmentation [J]. Chinese Journal of Dermatology, 2021, 54(5): 402-407.
[10]	Li Wenrui, Zhang Yuanyuan, Jia Weixue, He Yanyan, Xu Haoxiang, Lin Lin, Li Chengrang, . Effect of PSENEN gene silencing on the proliferation of and γ-secretase expression in HaCaT cells [J]. Chinese Journal of Dermatology, 2021, 54(4): 318-324.
[11]	Consensus Writing Group on the Diagnosis and Treatment of Acne Inversa/Hidradenitis Suppurativa in China. Diagnosis and treatment of acne inversa/hidradenitis suppurativa in China: an expert consensus statement （2021 version） [J]. Chinese Journal of Dermatology, 2021, 54(2): 97-104.
[12]	Shi Bei, Zhu Guannan, Fu Meng. Tumor necrosis factor-α inhibitors for the treatment of four cases of hidradenitis suppurativa [J]. Chinese Journal of Dermatology, 2021, 54(10): 901-903.
[13]	Zhang Wanlu, Zhang Yuanyuan, Wu Yingda, Cheng Ping, Li Wenrui, Xu Haoxiang, Wang Baoxi, He Yanyan, Li Chengrang. Effect of NCSTN gene silencing on the proliferation and differentiation of HaCaT cells [J]. Chinese Journal of Dermatology, 2020, 53(9): 704-709.
[14]	Xiao Xuemin, He Yanyan, Xu Haoxiang, Wang Baoxi, Lin Lihang. Genome-wide expression profile analysis of Nicastrin gene-silenced HaCaT cells [J]. Chinese Journal of Dermatology, 2020, 53(6): 445-451.
[15]	Chen Yudi, Liu Bo, Song Xiaoting, Zhao Zuotao. Clinical application of critical temperature threshold measurement in cold contact urticaria [J]. Chinese Journal of Dermatology, 2020, 53(5): 352-355.

Severity assessment criteria for acne inversa/hidradenitis suppurativa

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［30］

Related Articles 15

Metrics

Comments

Recommended 10